CEL-SCI Company Profile (NYSEMKT:CVM)

About CEL-SCI (NYSEMKT:CVM)

CEL-SCI logoCEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:CVM
  • CUSIP: N/A
  • Web: www.cel-sci.com
Capitalization:
  • Market Cap: $16.52 million
  • Outstanding Shares: 9,335,000
Average Prices:
  • 50 Day Moving Avg: $1.73
  • 200 Day Moving Avg: $1.28
  • 52 Week Range: $0.06 - $3.69
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.10
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $153,151.00
  • Price / Sales: 107.89
  • Book Value: ($0.58) per share
  • Price / Book: -3.05
Profitability:
  • EBITDA: ($27,120,000.00)
  • Net Margins: -25,564.75%
  • Return on Assets: -207.79%
Misc:
  • Average Volume: 217,750 shs.
  • Beta: -0.28
  • Short Ratio: 0.85
 

Frequently Asked Questions for CEL-SCI (NYSEMKT:CVM)

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "CVM."

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEMKT:CVM) announced its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.05) EPS for the quarter. The firm earned $0.02 million during the quarter. View CEL-SCI's Earnings History.

When will CEL-SCI make its next earnings announcement?

CEL-SCI is scheduled to release their next quarterly earnings announcement on Wednesday, December, 13th 2017. View Earnings Estimates for CEL-SCI.

Who are some of CEL-SCI's key competitors?

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the folowing people:

  • Geert R. Kersten Esq., Chief Executive Officer, Treasurer, Director
  • Patricia B Prichep, Senior Vice President - Operations, Corporate Secretary
  • John Cipriano, Senior Vice President - Regulatory Affairs
  • Daniel H Zimmerman Ph.D., Senior Vice President - Research, Cellular Immunology
  • Eyal Talor Ph.D., Chief Scientific Officer
  • Alexander G. Esterhazy, Independent Director
  • Peter R. Young Ph.D., Independent Director

How do I buy CEL-SCI stock?

Shares of CEL-SCI can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CEL-SCI's stock price today?

One share of CEL-SCI stock can currently be purchased for approximately $1.77.


MarketBeat Community Rating for CEL-SCI (NYSEMKT CVM)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  75
MarketBeat's community ratings are surveys of what our community members think about CEL-SCI and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CEL-SCI (NYSEMKT:CVM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for CEL-SCI (NYSEMKT:CVM)
Price Target History for CEL-SCI (NYSEMKT:CVM)
Analysts' Ratings History for CEL-SCI (NYSEMKT:CVM)
Show:
DateFirmActionRatingPrice TargetDetails
3/11/2016Dawson JamesReiterated RatingBuyView Rating Details
(Data available from 10/17/2015 forward)

Earnings

Earnings History for CEL-SCI (NYSEMKT:CVM)
Earnings by Quarter for CEL-SCI (NYSEMKT:CVM)
Earnings History by Quarter for CEL-SCI (NYSEMKT CVM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/12/2017N/AView Earnings Details
5/10/2017Q2 2017($0.05)$0.02 millionViewN/AView Earnings Details
2/9/2017Q116$0.01$0.01 millionViewN/AView Earnings Details
8/10/2016Q316($0.03)$0.13 millionViewN/AView Earnings Details
5/10/2016Q2($0.07)$0.03 millionViewN/AView Earnings Details
5/8/2015Q2 2015($0.12)($0.17)$0.10 million$0.20 millionViewN/AView Earnings Details
2/6/2015Q1 2015($0.09)($0.11)$0.07 million$0.14 millionViewN/AView Earnings Details
5/13/2014Q114($0.11)($0.24)$0.02 million$0.07 millionViewN/AView Earnings Details
2/11/2014Q413($0.11)($0.15)$510.39 millionViewN/AView Earnings Details
1/2/2014Q3($0.27)ViewN/AView Earnings Details
5/14/2013Q213($0.01)$0.07 millionViewN/AView Earnings Details
2/8/2013Q1 2013($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CEL-SCI (NYSEMKT:CVM)
Current Year EPS Consensus Estimate: $-0.42 EPS
Next Year EPS Consensus Estimate: $-0.29 EPS

Dividends

Dividend History for CEL-SCI (NYSEMKT:CVM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CEL-SCI (NYSEMKT:CVM)
Insider Trades by Quarter for CEL-SCI (NYSEMKT:CVM)
Insider Trades by Quarter for CEL-SCI (NYSEMKT:CVM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2017Eyal TalorInsiderSell769$1.91$1,468.79View SEC Filing  
8/16/2017Eyal TalorInsiderSell14,019$2.61$36,589.59View SEC Filing  
10/13/2014Geert R KerstenCEOBuy14,999$0.77$11,549.23View SEC Filing  
12/30/2013Geert R KerstenCEOBuy300,000$0.60$180,000.00View SEC Filing  
10/9/2013Geert R KerstenInsiderBuy8,400$0.79$6,636.00View SEC Filing  
6/19/2013Peter R YoungDirectorBuy25,000$0.24$6,000.00View SEC Filing  
6/14/2013Geert R KerstenInsiderBuy145,120$0.24$34,828.80View SEC Filing  
5/20/2013Geert R KerstenCEOBuy40,000$0.25$10,000.00View SEC Filing  
5/2/2013Geert R KerstenCEOBuy118,700$0.27$32,049.00View SEC Filing  
3/27/2013Peter R YoungDirectorBuy25,000$0.23$5,750.00View SEC Filing  
3/26/2013Geert R KerstenCEOBuy348,125$0.21$73,106.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CEL-SCI (NYSEMKT:CVM)
Latest Headlines for CEL-SCI (NYSEMKT:CVM)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to CEL-SCI Corp. : October 11, 2017
finance.yahoo.com - October 11 at 7:11 PM
finance.yahoo.com logoCEL-SCI Granted European Patent for Multikine’s Mechanism of Action in Making Tumors ‘Visible’ to the Immune System
finance.yahoo.com - October 10 at 3:24 PM
businesswire.com logoCEL-SCI Announces Update on Ongoing Arbitration against Former Clinical Research Organization - Business Wire (press release)
www.businesswire.com - October 5 at 10:45 AM
finance.yahoo.com logoCEL-SCI Announces Update on Ongoing Arbitration against Former Clinical Research Organization
finance.yahoo.com - October 5 at 10:45 AM
finance.yahoo.com logoETFs with exposure to CEL-SCI Corp. : September 22, 2017
finance.yahoo.com - September 22 at 4:43 PM
finance.yahoo.com logoCEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine
finance.yahoo.com - September 19 at 5:38 PM
businesswire.com logoCEL-SCI to Present Today at the 19th Annual Rodman & Renshaw Global Investment Conference - Business Wire (press release)
www.businesswire.com - September 11 at 11:20 PM
finance.yahoo.com logoETFs with exposure to CEL-SCI Corp. : September 12, 2017
finance.yahoo.com - September 11 at 11:20 PM
finance.yahoo.com logoCEL-SCI to Present Today at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 11 at 6:19 PM
finance.yahoo.com logoETFs with exposure to CEL-SCI Corp. : August 31, 2017
finance.yahoo.com - August 31 at 10:39 PM
businesswire.com logoCEL-SCI to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 11, 2017 - Business Wire (press release)
www.businesswire.com - August 30 at 6:47 PM
finance.yahoo.com logoCEL-SCI to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 11, 2017
finance.yahoo.com - August 30 at 6:47 PM
businesswire.com logoCEL-SCI Extends the Expiration Date of Series DD and Series EE ... - Business Wire (press release)
www.businesswire.com - August 29 at 11:08 PM
finance.yahoo.com logoCEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued in December 2016
finance.yahoo.com - August 29 at 6:04 PM
finance.yahoo.com logoCEL-SCI Corp. :CVM-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:49 PM
streetinsider.com logoCEL-SCI Corp (CVM) Announces 1.75M Share Registered Direct Common Offering at $2/Sh - StreetInsider.com
www.streetinsider.com - August 24 at 12:44 AM
streetinsider.com logoCEL-SCI Corp (CVM) Announces 1.75M Share Registered Direct Common Offering at $2/Sh
www.streetinsider.com - August 23 at 7:40 PM
finance.yahoo.com logoCEL-SCI Announces $3.5 Million Registered Direct Offering
finance.yahoo.com - August 23 at 7:40 PM
americanbankingnews.com logoInsider Selling: CEL-SCI Co. (CVM) Insider Sells 14,019 Shares of Stock
www.americanbankingnews.com - August 17 at 8:50 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and CEL-SCI Corporation
finance.yahoo.com - August 15 at 6:21 PM
nasdaq.com logoMid-Day Market Update: Sorl Auto Parts Drops After Q2 Results; CEL-SCI Shares Surge - Nasdaq
www.nasdaq.com - August 15 at 4:08 AM
streetinsider.com logoMorning Movers 8/14: (CVM) (NEFF) (EGLT) (FCAU) (ZYNE) - StreetInsider.com
www.streetinsider.com - August 14 at 6:01 PM
benzinga.com logoMid-Day Market Update: Sorl Auto Parts Drops After Q2 Results; CEL-SCI Shares Surge - Benzinga
www.benzinga.com - August 14 at 6:01 PM
bizjournals.com logoFDA lifts hold on Cel-Sci's clinical trial for head and neck cancer drug - Washington Business Journal
www.bizjournals.com - August 14 at 6:01 PM
finance.yahoo.com logoU.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial
finance.yahoo.com - August 14 at 6:01 PM
finance.yahoo.com logoBiotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward
finance.yahoo.com - August 14 at 6:01 PM
finance.yahoo.com logoCel-Sci reports 3Q loss
finance.yahoo.com - August 9 at 10:49 PM
finance.yahoo.com logoCEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results
finance.yahoo.com - August 9 at 5:49 PM
americanbankingnews.com logoCEL-SCI Co. (CVM) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:16 AM
streetinsider.com logoCEL-SCI Corp (CVM) Says FDA Requested Changes to Multikine Investigator Brochure - StreetInsider.com
www.streetinsider.com - June 29 at 11:57 PM
streetinsider.com logoCEL-SCI Corp (CVM) Received Subscription Agreements for Sale of ... - StreetInsider.com
www.streetinsider.com - June 22 at 10:04 PM
nasdaq.com logoMid-Day Market Update: Cavco Rises After Q4 Results; CEL-SCI Shares Plunge
www.nasdaq.com - June 13 at 4:16 PM
streetinsider.com logoCEL-SCI Corp (CVM) Plans 1-for-25 Reverse Stock Split - StreetInsider.com
www.streetinsider.com - June 12 at 5:34 PM
streetinsider.com logoCEL-SCI Corp (CVM) Responds to FDA for Phase 3 Head and Neck Cancer Trial - StreetInsider.com
www.streetinsider.com - June 5 at 4:36 PM
us.rd.yahoo.com logoCEL-SCI Announces $1.5 Million Registered Direct Offering
us.rd.yahoo.com - March 9 at 5:10 PM
us.rd.yahoo.com logoCEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine
us.rd.yahoo.com - March 6 at 10:18 AM
streetinsider.com logoCEL-SCI Corp (CVM) Says NYSE Approves Plan to Bring Itself Into Compliance with Listing Standards - StreetInsider.com
www.streetinsider.com - March 1 at 11:18 PM
bizjournals.com logoVienna's Cel-Sci Corp. raises $1 million for head and neck cancer trial - Washington Business Journal
www.bizjournals.com - March 1 at 11:18 PM
biz.yahoo.com logoCEL SCI CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 28 at 10:34 AM
us.rd.yahoo.com logoCEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference
us.rd.yahoo.com - February 21 at 5:55 PM
biz.yahoo.com logoCEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
biz.yahoo.com - February 21 at 5:55 PM
us.rd.yahoo.com logoCEL-SCI Announces $1.0 Million Registered Direct Offering
us.rd.yahoo.com - February 17 at 3:38 PM
us.rd.yahoo.com logo8:31 am CEL-SCI Corp commences approx. $1.0 mln direct offering of common stock; will issue approximately 10 million registered shares of common stock at a purchase price of $0.10 per share
us.rd.yahoo.com - February 17 at 3:38 PM
us.rd.yahoo.com logoCEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results
us.rd.yahoo.com - February 10 at 3:06 AM
biz.yahoo.com logoCEL SCI CORP Files SEC form 8-K, Other Events
biz.yahoo.com - December 22 at 9:47 PM
businesswire.com logoCEL-SCI Announces Closing of Public Offering and Receives Audit ... - Business Wire (press release)
www.businesswire.com - December 21 at 10:24 PM

Social

Chart

CEL-SCI (CVM) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.